PNN DigitalPNN Digital
    Facebook Twitter Instagram
    Sunday, June 1
    Trending
    • Aayush Wellness’s FY25 Revenue Rockets 8,645%, Net Profit Soars 489%
    • Aristo Bio-Tech FY25 PAT Rises to Rs 4.06 Cr, Revenue Jumps 30 Percent to Rs 318.09 Cr
    • IFL Enterprises Ltd reports stellar turnaround in FY25; PAT up 348 Percent Y-o-Y to Rs. 3.04 crore in Q4FY25
    • Deliure Unveils Exclusive Tres Leches Cakes for Mumbai’s Dessert Lovers
    • WARF Invites Colleges to Join India’s Top 2025 Ranking Survey for Engineering, Medical, MBA and Law
    • Maximus International’s Momentum Continues: Strategic Investments Fuel 26 Percent EBITDA Growth
    • Profin Range of Aluminium Profiles by Hafele
    • Business Outline Announces the Business Elite Award | Recognising Exceptional Business Leaders and Companies
    Submit News
    Twitter LinkedIn Instagram
    PNN DigitalPNN Digital
    Subscribe
    • Home
    • News
    • Business
    • Entertainment
    • National
    • Lifestyle
    • More
      • Sports
      • Health
      • Finance
      • Education
    PNN DigitalPNN Digital
    Home»Business

    Remedium Lifecare Rights Issue Gains Momentum: 26% Subscribed Within First Two Days

    PNN NewsdeskPNN NewsdeskUpdated:08/05/2025 Business 3 Mins Read
    Remedium
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Mumbai (Maharashtra) [India], May 5: The Rights Issue of Remedium Lifecare Ltd marks a significant milestone in the company’s growth journey. Remedium Lifecare is a rapidly growing company specializing in the trading and distribution of raw materials as part of supply chain management for the pharmaceutical industry. The issue has been receiving tremendous response from investors and shareholders, with a subscription of 26.03% by the end of Day 2.

    The capital raised will be strategically utilized to accelerate global expansion initiatives, strengthen the company’s footprint in key international markets, and strengthening working capital, Investment in R&D capabilities thereby improving the overall financial health of the organization. By reinforcing its balance sheet and enhancing operational capabilities, Remedium Lifecare aims to unlock significant long-term value for its investors, positioning itself as a leading player in the global specialty chemicals and pharmaceutical sectors.

    Adarsh Munjal, Whole Time Director of Remedium Lifecare Ltd said: “This move will not only improve our financial health but also set the stage for significant growth. Our focus is on expanding our global footprint and advancing in research and manufacturing to serve a broader market. This approach will ensure our long-term sustainability and success.”

    This strategic shift follows the company’s recent achievement of securing a ₹182.7 crore multiyear export order from a prominent UK-based pharmaceutical distributor in February 2025. The order positions Remedium as a credible global supplier of pharmaceutical intermediates in the anti-infective, cardiovascular, and CNS therapeutic segments.

    Participation in the rights issue represents more than a capital contribution; it reflects alignment with a company prioritizing sound financial management, enhanced operational flexibility, and strategic global expansion.

    Key Highlights:

    • Remedium Lifecare offers a rights issue at ₹1 per share (61:50), against a ₹1.85 closing price on 2nd May 2025.
    • The renunciation window runs from April 30 to May 9, 2025, and the rights issue closes on May 14, 2025.
    • Proceeds from the rights issue will be used for expansion of R&D capabilities and working capital
    • The company plans to expand contract manufacturing in CDMO, invest in research, and tap global markets.

    About Remedium Lifecare Ltd.:

    Founded in 1988, Remedium Lifecare Ltd. is a BSE-listed pharmaceutical company engaged in the trading and distribution of raw material as a supply chain management for the pharmaceutical industry with an emphasis on quality, compliance, and global reach, the company continues to expand its presence while playing a pivotal role in India’s pharmaceutical ecosystem

    For more Information, contact: Adarsh Munjal at [email protected]

    If you have any objection to this press release content, kindly contact [email protected] to notify us. We will respond and rectify the situation in the next 24 hours.

    26% Subscribed First Two Days Gains Momentum Remedium Lifecare Rights Issue
    PNN Newsdesk

    Keep Reading

    Aayush Wellness’s FY25 Revenue Rockets 8,645%, Net Profit Soars 489%

    Aristo Bio-Tech FY25 PAT Rises to Rs 4.06 Cr, Revenue Jumps 30 Percent to Rs 318.09 Cr

    IFL Enterprises Ltd reports stellar turnaround in FY25; PAT up 348 Percent Y-o-Y to Rs. 3.04 crore in Q4FY25

    Deliure Unveils Exclusive Tres Leches Cakes for Mumbai’s Dessert Lovers

    WARF Invites Colleges to Join India’s Top 2025 Ranking Survey for Engineering, Medical, MBA and Law

    Maximus International’s Momentum Continues: Strategic Investments Fuel 26 Percent EBITDA Growth

    Recent Posts
    • Aayush Wellness’s FY25 Revenue Rockets 8,645%, Net Profit Soars 489%
    • Aristo Bio-Tech FY25 PAT Rises to Rs 4.06 Cr, Revenue Jumps 30 Percent to Rs 318.09 Cr
    • IFL Enterprises Ltd reports stellar turnaround in FY25; PAT up 348 Percent Y-o-Y to Rs. 3.04 crore in Q4FY25
    • Deliure Unveils Exclusive Tres Leches Cakes for Mumbai’s Dessert Lovers
    • WARF Invites Colleges to Join India’s Top 2025 Ranking Survey for Engineering, Medical, MBA and Law

    Aayush Wellness’s FY25 Revenue Rockets 8,645%, Net Profit Soars 489%

    31/05/2025

    Aristo Bio-Tech FY25 PAT Rises to Rs 4.06 Cr, Revenue Jumps 30 Percent to Rs 318.09 Cr

    31/05/2025

    IFL Enterprises Ltd reports stellar turnaround in FY25; PAT up 348 Percent Y-o-Y to Rs. 3.04 crore in Q4FY25

    31/05/2025

    Deliure Unveils Exclusive Tres Leches Cakes for Mumbai’s Dessert Lovers

    30/05/2025

    WARF Invites Colleges to Join India’s Top 2025 Ranking Survey for Engineering, Medical, MBA and Law

    30/05/2025

    Maximus International’s Momentum Continues: Strategic Investments Fuel 26 Percent EBITDA Growth

    30/05/2025
    Facebook Twitter Pinterest Vimeo WhatsApp TikTok Instagram

    MENU

    • Home
    • Business
    • Education
    • Home
    • Business
    • Education
    • National
    • Lifestyle

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    © 2025 PNN Digital. Designed by Primex Media Services.
    • About Us
    • Legal Disclaimer
    • Privacy Policy
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.